Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of genetic targets on primary brain tumor therapy: what's ready for prime time?

Advances in experimental medicine and biology - 1 Jan 2013

Zalatimo O, Zoccoli C M, Patel A, Weston C L, Glantz M

Abstract excerpt

Primary brain tumors constitute a substantial public health problem with 66,290 cases diagnosed in the US in 2012, and 13,700 deaths recorded. With discovery of genetic factors associated with specific brain tumor subtypes, the goal of therapy is changing from treating a class of tumors to develo...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Chromosome Deletion
Share to DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Modification Methylases

Share to DNA Repair Enzymes

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Tumor Suppressor Proteins

Source

Identifiers

PMID: 23288644
DOI: 10.1007/978-1-4614-6176-0_12

Genes

MGMT
IDH1
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23288644-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of genetic targets on primary brain tumor therapy: what's ready for prime time?PMID 23288644Read ↗

Clinical impact of molecular biomarkers in gliomas.Semantic proximity Read ↗

Perspectives of Personalized Chemotherapy of Gliomas Based on Molecular Tumor Profiling.Semantic proximity Read ↗

Incorporating Advances in Molecular Pathology Into Brain Tumor DiagnosticsSemantic proximity Read ↗

Molecular neuro-oncology in clinical practice: a new horizon.Semantic proximity Read ↗

Molecular biology of high-grade gliomas: what should the clinician know?Semantic proximity Read ↗

Molecular pathology in adult high‐grade gliomas: from molecular diagnostics to target therapiesSemantic proximity Read ↗

Clinical impact of molecular profiling in rare brain tumors.Semantic proximity Read ↗

Prognostic and predictive biomarkers in central nervous system tumours: the molecular state of play.Semantic proximity Read ↗

[How molecular biology can improve the clinical diagnosis of gliomas?]Semantic proximity Read ↗

The Role of Molecular Diagnostics in the Management of Patients with Gliomas.Semantic proximity Read ↗

Clinical prognostic value of isocitrate dehydrogenase mutation, O-6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in glioma patientsSemantic proximity Read ↗

Unlocking new horizons: advances in treating IDH-mutant, 1p/19q-codeleted oligodendrogliomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.